159 related articles for article (PubMed ID: 34182590)
1. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):635-641. PubMed ID: 28089878
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.
Achini-Gutzwiller FR; Schilham MW; von Asmuth EGJ; Jansen-Hoogendijk AM; Jol-van der Zijde CM; van Tol MJD; Bredius RGM; Güngör T; Lankester AC; Moes DJAR
Blood Adv; 2023 Aug; 7(16):4462-4474. PubMed ID: 37285798
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.
Nijstad AL; Nierkens S; Lindemans CA; Boelens JJ; Bierings M; Versluys AB; van der Elst KCM; Huitema ADR
Br J Clin Pharmacol; 2021 Aug; 87(8):3218-3226. PubMed ID: 33444472
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
Wang H; Jones AK; Dvorak CC; Huang L; Orchard P; Ivaturi V; Long-Boyle J
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1603-1610. PubMed ID: 31002993
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.
Admiraal R; Jol-van der Zijde CM; Furtado Silva JM; Knibbe CAJ; Lankester AC; Boelens JJ; Hale G; Etuk A; Wilson M; Adams S; Veys P; van Kesteren C; Bredius RGM
Clin Pharmacokinet; 2019 Dec; 58(12):1609-1620. PubMed ID: 31131436
[TBL] [Abstract][Full Text] [Related]
11. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders.
Chandra S; Mizuno K; Zhao J; Davies SM; Marsh RA; Fukuda T; Setchell KDR; Vinks AA; Mehta PA
Br J Clin Pharmacol; 2022 Jan; 88(1):115-127. PubMed ID: 34075614
[TBL] [Abstract][Full Text] [Related]
12. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
14. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
[TBL] [Abstract][Full Text] [Related]
15. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.
van Hoogdalem MW; Emoto C; Fukuda T; Mizuno T; Mehta PA; Vinks AA
Br J Clin Pharmacol; 2020 May; 86(5):933-943. PubMed ID: 31851762
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.
Langenhorst JB; Dorlo TPC; van Maarseveen EM; Nierkens S; Kuball J; Boelens JJ; van Kesteren C; Huitema ADR
Clin Pharmacokinet; 2019 May; 58(5):627-637. PubMed ID: 30327943
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation.
Zwart TC; Bezstarosti S; Achini FR; Reinders MEJ; Schilham MW; Heidt S; Guchelaar HJ; de Fijter JW; Moes DJAR
Br J Clin Pharmacol; 2023 Apr; 89(4):1471-1485. PubMed ID: 36408784
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
